Citi analyst Geoff Meacham reinstated coverage of Merck (MRK) with a Neutral rating and $125 price target Citi views the company’s Q1 report as solid but wants to see positive clinical catalysts and more business development before recommending the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MRK:
- FDA blocked publication of studies showing Covid vaccine safe, NYT says
- Trump Trade: Microsoft, Google agree to U.S. security reviews of AI models
- Merck completes Terns Pharmaceuticals acquisition
- Moderna price target raised to $33 from $30 at Morgan Stanley
- Merck price target raised to $112 from $109 at Morgan Stanley